Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 27
---
ive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be limited by applicable law. The Board of Directors, or any committee
thereof, has approved the resolutions (the “”) substantially in the form provided to the Investor
to authorize this Agreement, the Registration Rights Agreement and the transactions contemplated hereby and thereby. The Signing Resolutions
are valid, in full force and effect and have not been modified or supplemented in any respect. The Company has delivered to the Investor
a true and correct copy of minutes of a meeting of the Board of Directors, or any committee thereof, at which the Signing Resolutions
were duly adopted by the Board of Directors or a unanimous written consent adopting the Signing Resolutions executed by all of the members
of the Board of Directors or any committee thereof. Except as set forth in this Agreement, no other approvals or consents of the Board
of Directors, any authorized committee thereof, or shareholders (except as provided in this Agreement) is necessary under applicable laws
and the Articles of Association (as defined below) to authorize the execution and delivery of the Transaction Documents or any of the
transactions contemplated thereby, including, but not limited to, the allotment of the Purchase Shares and, if applicable, the Commitment
Shares.

(c) .
As of the Execution Date, the authorized share capital of the Company is set forth on Section 4(c) of the Disclosure Schedule. Except
as disclosed in the SEC Documents (as defined below) or in Section 4(c) of the Disclosure Schedule, (i) none of the Company’s share
capital is subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company,
(ii) there are no outstanding debt securities, (iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible into, any share capital of the Company or
any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is
or may become bound to issue additional share capital of the Company or any of its Subsidiaries or options, warrants, scrip, rights to
subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any share capital
of the Company or any of its Subsidiaries, (iv) there